% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gebhardt:166641,
      author       = {C. Gebhardt$^*$ and S. C. S. Simon$^*$ and R. Weber$^*$ and
                      M. Gries$^*$ and D. H. Mun$^*$ and R. Reinhard and T.
                      Holland-Letz$^*$ and V. Umansky$^*$ and J. Utikal$^*$},
      title        = {{P}otential therapeutic effect of low-dose paclitaxel in
                      melanoma patients resistant to immune checkpoint blockade:
                      {A} pilot study.},
      journal      = {Cellular immunology},
      volume       = {360},
      issn         = {0008-8749},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2021-00008},
      pages        = {104274},
      year         = {2021},
      note         = {Volume 360, February 2021, 104274#EA:A370#LA:A370#},
      abstract     = {The low dose application of chemotherapeutic agents such as
                      paclitaxel was previously shown to initiate anti-tumor
                      activity by neutralizing myeloid-derived suppressor cells
                      (MDSCs) in melanoma mouse models. Here, we investigated
                      immunomodulating effects of low-dose paclitaxel in 9
                      metastatic melanoma patients resistant to prior treatments.
                      Three patients showed response to therapy (two partial
                      responses and one stable disease). In responding patients,
                      paclitaxel decreased the frequency and immunosuppressive
                      pattern of MDSCs in the peripheral blood and skin
                      metastases. Furthermore, paclitaxel modulated levels of
                      inflammatory mediators in the serum. In addition, responders
                      displayed enhanced frequencies of tumor-infiltrating CD8+ T
                      cells and their activity indicated by the upregulation of
                      CD25 and TCR ζ-chain expression. Our study suggests that
                      low-dose paclitaxel treatment could improve clinical outcome
                      of some advanced melanoma patients by enhancing anti-tumor
                      immunity and might be proposed for combined melanoma
                      immunotherapy.},
      keywords     = {Immune checkpoint blockade (Other) / Immunotherapy (Other)
                      / Melanoma (Other) / Myeloid suppressor cells (Other) /
                      Paclitaxel (Other)},
      cin          = {A370 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)A370-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33383383},
      doi          = {10.1016/j.cellimm.2020.104274},
      url          = {https://inrepo02.dkfz.de/record/166641},
}